Organon & Co | OGN - Gross Profit On Sales

Stock Price
8.19
Daily Change
0.09 1.11%
Monthly
0%
Yearly
-44.00%
Q1 Forecast
8.28

Organon & Co reported $857M in Gross Profit on Sales for its fiscal quarter ending in September of 2025.





Gross Profit On Sales Change Date
Bristol-Myers Squibb USD 8.79B 110M Sep/2025
Celltrion KRW 626.11B 81.75B Sep/2025
Cspc Pharmaceutical CNY 4.34B 333.68M Sep/2025
Dianthus Therapeutics USD 396K 203K Sep/2025
Divis Laboratories Ltd INR 14.54B 1.5B Jun/2025
Gilead Sciences USD 5.58B 453M Jun/2025
Glaxosmithkline GBP 8.75B 2.92B Sep/2025
Kangmei Pharma CNY 270.29M 20.26M Sep/2025
Knight Therapeutics CAD 44.83M 9.96M Jun/2025
Laboratorios Farma EUR 105.28M 177.08M Jun/2025
Medical Developments International AUD 7.35M 7.37M Jun/2025
Merck USD 13.42B 431M Sep/2025
Neuren Pharmaceuticals AUD 6.69M 6.37M Jun/2025
Novartis USD 10.82B 694M Sep/2025
Organigram Holdings CAD 31.84M 23.88M Sep/2025
Organon & Co USD 857M 17M Sep/2025
Pharma Mar EUR 33.36M 20.25M Sep/2025
Qiagen NV USD 344.8M 10.51M Sep/2025
Sartorius EUR 393.2M 23M Sep/2025
Sino Biopharmaceutical CNY 10.5B 2.53B Dec/2024
Tilray USD 67.63M 15.62M Mar/2025